⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Alcohol SCHEMBL16114773 | 0.88 | — | — | |
| SCHEMBL8486633 | 0.79 | — | — | |
| SCHEMBL25220166 | 0.76 | — | — | |
| SCHEMBL31599631 | 0.76 | — | — | |
| SCHEMBL5653886 | 0.73 | — | — | |
| SCHEMBL7630104 | 0.73 | — | — | |
| SCHEMBL1564510 | 0.71 | — | — | |
| SCHEMBL31121561 | 0.71 | — | — | |
| SCHEMBL20886323 | 0.71 | — | — | |
| SCHEMBL14683300 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115135656-B | Furanoindazole derivatives | 拜耳公司 | 2024-06-14 | — | — | CN | claimed |
| WO-2024091542-A1 | COMPOUNDS AND COMPOSITIONS AS GPR52 MODULATORS | NEUROCRINE BIOSCIENCES, INC. (US) | 2024-05-02 | — | — | WO | claimed |
| WO-2024083705-A1 | FUROINDAZOLE DERIVATIVES FOR THE TREATMENT OF PAIN | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-25 | — | — | WO | claimed |
| CN-117062815-A | VMAT2 inhibitors and methods of use | 纽罗克里生物科学有限公司 | 2023-11-14 | — | — | CN | claimed |
| EP-4168409-A1 | VMAT2 INHIBITORS AND METHODS OF USE | Neurocrine Biosciences, Inc. (US) | 2023-04-26 | — | — | EP | claimed |
| US-20230112499-A1 | FUROINDAZOLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | claimed |
| CN-107793381-B | Preparation method of 3-fluoro-oxetane-3-methanol and intermediate thereof | 上海睿智化学研究有限公司 | 2022-12-23 | — | — | CN | claimed |
| CN-115135656-A | Furanoinindazole derivatives | 拜耳公司 | 2022-09-30 | — | — | CN | claimed |
| WO-2021122415-A9 | FUROINDAZOLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-06-30 | — | — | WO | claimed |
| WO-2021122415-A1 | FUROINDAZOLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-24 | — | — | WO | claimed |
| CN-107793381-A | The preparation method of the methanol of 3 fluoro-oxetane 3 and its intermediate | 上海睿智化学研究有限公司 | 2018-03-13 | — | — | CN | claimed |
| US-9708334-B2 | Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine compounds as GlyT1 inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-07-18 | — | — | US | claimed |
| EP-3134406-A1 | SUBSTITUTED 2,4,5,6-TETRAHYDROPYRROLO[3,4-C]PYRAZOLE AND 4,5,6,7-TETRAHYDRO-2H-PYRAZOLO [4,3-C]PYRIDINE COMPOUNDS AS GLYT1 INHIBITORS | Dart Neuroscience (Cayman) Ltd (KY) | 2017-03-01 | — | — | EP | claimed |
| US-20170044167-A1 | SUBSTITUTED 2,4,5,6-TETRAHYDROPYRROLO[3,4-C]PYRAZOLE AND 4,5,6,7-TETRAHYDRO-2H-PYRAZOLO[4,3-C]PYRIDINE COMPOUNDS AS GLYT1 INHIBITORS | DART NEUROSCIENCE LLC | 2017-02-16 | — | — | US | claimed |
| WO-2016160677-A1 | COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2016-10-06 | — | — | WO | claimed |
| WO-2015164520-A1 | SUBSTITUTED 2,4,5,6-TETRAHYDROPYRROLO[3,4-C] PYRAZOLE AND 4,5,6,7-TETRAHYDRO-2H-PYRAZOLO [4,3-C] PYRIDINE COMPOUNDS AS GLYT1 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2015-10-29 | — | — | WO | claimed |
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | BIOGEN MA INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260027211-A1 | ULTRASOUND MEDIATED DELIVERY OF DRUGS | EXACT THERAPEUTICS AS (NO) | 2026-01-29 | — | — | US | disclosed |
| WO-2006045416-A1 | QUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-04 | — | — | WO | disclosed |
| US-20060084679-A1 | Quinoline derivatives as H3R inverse agonists | HOFFMANN-LA ROCHE INC. | 2006-04-20 | — | — | US | disclosed |